Skip to main content

Researchers eye up new gene therapy trial that could reverse hereditary blindness

Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (NIHR) and Moorfields Eye Charity.


LHON
Dr Patrick Yu Wai Man

Honorary Consultant Ophthalmologist

Addenbrooke’s Hospital

The two most common inherited optic neuropathies are Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (DOA).

The management of patients with inherited optic neuropathies remains challenging as there are limited treatment options to slow or prevent ongoing loss of vision.

Dr Yu Wai Man and colleagues have successfully used a gene therapy product to replace the defective gene that causes LHON in patients carrying a specific mutation. Results so far show that those who were treated within 1 year of being affected experienced significant improvement in their vision. These results were published in Science translational medicine. Fortunately therefore, important progress is being made but there are still many questions to address. With his Advanced Fellowship, Patrick will tackle some of the unanswered questions in LHON and DOA.

The trial is funded by an NIHR Moorfields Eye Charity Advanced Fellowship and supported by the NIHR Cambridge Biomedical Research Centre (BRC).

For more information visit: Moorfields Eye Charity Research and Innovation

Published September 1 2021

Latest from CCTU

Targeting the immune system could prevent future heart attacks, Cambridge-led trial suggests

Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…

Cambridge study finds hot flush treatment has anti-breast cancer activity

A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast…

Innovative trial offers hope on World Pancreatic Cancer Day

An early-stage trial, recently opened at Addenbrooke's Hospital, offers new hope to people with late-stage pancreatic cancer and their families.

All news